Sight Sciences (NASDAQ:SGHT) CFO Sells 6,902 Shares

Sight Sciences, Inc. (NASDAQ:SGHT) CFO James Rodberg sold 6,902 shares of the business’s stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $5.36, for a total value of $36,994.72. Following the sale, the chief financial officer directly owned 224,037 shares in the company, valued at approximately $1,200,838.32. The trade was a 2.99% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Sight Sciences Stock Performance

Shares of NASDAQ SGHT opened at $5.48 on Tuesday. Sight Sciences, Inc. has a 1 year low of $3.11 and a 1 year high of $9.24. The firm has a market cap of $298.17 million, a P/E ratio of -7.72 and a beta of 2.38. The stock has a fifty day moving average price of $4.95 and a two-hundred day moving average price of $5.31. The company has a debt-to-equity ratio of 0.68, a quick ratio of 5.48 and a current ratio of 5.86.

Sight Sciences (NASDAQ:SGHT) last announced its earnings results on Wednesday, May 6th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.05). The firm had revenue of $19.70 million for the quarter, compared to the consensus estimate of $18.46 million. Sight Sciences had a negative net margin of 46.83% and a negative return on equity of 52.34%. Research analysts forecast that Sight Sciences, Inc. will post -0.6 EPS for the current fiscal year.

Institutional Investors Weigh In On Sight Sciences

Hedge funds have recently made changes to their positions in the company. Alliancebernstein L.P. boosted its stake in Sight Sciences by 5.5% in the 3rd quarter. Alliancebernstein L.P. now owns 34,380 shares of the company’s stock worth $118,000 after purchasing an additional 1,800 shares during the period. Deutsche Bank AG lifted its holdings in shares of Sight Sciences by 9.8% in the fourth quarter. Deutsche Bank AG now owns 27,355 shares of the company’s stock valued at $217,000 after purchasing an additional 2,439 shares in the last quarter. Tower Research Capital LLC TRC lifted its holdings in shares of Sight Sciences by 32.7% in the second quarter. Tower Research Capital LLC TRC now owns 11,665 shares of the company’s stock valued at $48,000 after purchasing an additional 2,875 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Sight Sciences by 1.0% in the third quarter. Dimensional Fund Advisors LP now owns 303,634 shares of the company’s stock worth $1,045,000 after buying an additional 3,051 shares during the period. Finally, BNP Paribas Financial Markets grew its holdings in shares of Sight Sciences by 99.8% during the third quarter. BNP Paribas Financial Markets now owns 7,579 shares of the company’s stock valued at $26,000 after buying an additional 3,785 shares in the last quarter. Hedge funds and other institutional investors own 55.51% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently weighed in on SGHT. Citigroup raised their target price on shares of Sight Sciences from $4.35 to $5.15 and gave the stock a “neutral” rating in a report on Thursday, May 28th. Weiss Ratings cut Sight Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, May 11th. Five analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Sight Sciences currently has a consensus rating of “Hold” and a consensus price target of $8.14.

Sight Sciences Company Profile

Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company’s flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye’s natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.

Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.